Cargando…

Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis

Small cell carcinoma of the ovary (SCCO) is a rare type of ovarian cancer with high aggressiveness. The optimal treatment modality remains elusive. This study aims to comprehensively investigate the survival impact of clinical characteristics and treatments including lymphadenectomy in SCCO. A retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Ning, Yan, Du, Yan, Kang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600050/
https://www.ncbi.nlm.nih.gov/pubmed/36290894
http://dx.doi.org/10.3390/curroncol29100617
_version_ 1784816744973467648
author Wang, Jing
Ning, Yan
Du, Yan
Kang, Yu
author_facet Wang, Jing
Ning, Yan
Du, Yan
Kang, Yu
author_sort Wang, Jing
collection PubMed
description Small cell carcinoma of the ovary (SCCO) is a rare type of ovarian cancer with high aggressiveness. The optimal treatment modality remains elusive. This study aims to comprehensively investigate the survival impact of clinical characteristics and treatments including lymphadenectomy in SCCO. A retrospective cohort study was performed and included patients from the Surveillance, Epidemiology, and End Results (SEER) database. Data collected included demographics, therapeutic details, and pathologic characteristics. Propensity-score matching analysis (PSM) was carried out to balance baseline variables between SCCO and non-SCCO. Cox regression, Kaplan–Meier, and stratified analyses were conducted before and after PSM. After filtering, 80 records on SCCO and 39,662 records on non-SSCO were obtained. Patients with SCCO were more prone to present unilateral tumor (57.6% and 85.0%, p < 0.001), larger tumor size (>15 cm: 9.5% and 32.5%; 10–15 cm: 13.2% vs. 22.5%, p < 0.001), younger age (59.1 ± 14.91 vs. 37.2 ± 19.05; p < 0.001), single status (17.0% vs. 45.0%; p < 0.001), single malignant tumor in a lifetime (76.1% vs. 87.5%; p = 0.0244), and pathologic grade IV diseases (14.5% vs. 40.0%; p < 0.001) compared with non-SCCO. After balancing the baseline clinical characteristics with a 1:4 ratio PSM, a total of matched 72 patients with SCCO and 254 patients with non-SCCO were identified. The survival rate of SCCO was distinctly inferior to non-SCCO, particularly in FIGO I, II, and III stages. Lymphadenectomy was performed in 37 (51.39%) SCCO patients, of whom 12 (32.43%) were found to have pathologically positive lymph nodes. Lymphadenectomy was linked to favorable overall survival in SCCO, particularly in the advanced stage, and was also an independent prognostic factor, whereas lymphadenectomy did not reveal an edge in matched non-SCCO. There was a pronounced survival benefit for SCCO when at least 10 or more nodes were resected. Lymphadenectomy in a non-stage-dependent way should be considered and deserves further clinical validation to promote the overall survival in SCCO.
format Online
Article
Text
id pubmed-9600050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96000502022-10-27 Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis Wang, Jing Ning, Yan Du, Yan Kang, Yu Curr Oncol Article Small cell carcinoma of the ovary (SCCO) is a rare type of ovarian cancer with high aggressiveness. The optimal treatment modality remains elusive. This study aims to comprehensively investigate the survival impact of clinical characteristics and treatments including lymphadenectomy in SCCO. A retrospective cohort study was performed and included patients from the Surveillance, Epidemiology, and End Results (SEER) database. Data collected included demographics, therapeutic details, and pathologic characteristics. Propensity-score matching analysis (PSM) was carried out to balance baseline variables between SCCO and non-SCCO. Cox regression, Kaplan–Meier, and stratified analyses were conducted before and after PSM. After filtering, 80 records on SCCO and 39,662 records on non-SSCO were obtained. Patients with SCCO were more prone to present unilateral tumor (57.6% and 85.0%, p < 0.001), larger tumor size (>15 cm: 9.5% and 32.5%; 10–15 cm: 13.2% vs. 22.5%, p < 0.001), younger age (59.1 ± 14.91 vs. 37.2 ± 19.05; p < 0.001), single status (17.0% vs. 45.0%; p < 0.001), single malignant tumor in a lifetime (76.1% vs. 87.5%; p = 0.0244), and pathologic grade IV diseases (14.5% vs. 40.0%; p < 0.001) compared with non-SCCO. After balancing the baseline clinical characteristics with a 1:4 ratio PSM, a total of matched 72 patients with SCCO and 254 patients with non-SCCO were identified. The survival rate of SCCO was distinctly inferior to non-SCCO, particularly in FIGO I, II, and III stages. Lymphadenectomy was performed in 37 (51.39%) SCCO patients, of whom 12 (32.43%) were found to have pathologically positive lymph nodes. Lymphadenectomy was linked to favorable overall survival in SCCO, particularly in the advanced stage, and was also an independent prognostic factor, whereas lymphadenectomy did not reveal an edge in matched non-SCCO. There was a pronounced survival benefit for SCCO when at least 10 or more nodes were resected. Lymphadenectomy in a non-stage-dependent way should be considered and deserves further clinical validation to promote the overall survival in SCCO. MDPI 2022-10-16 /pmc/articles/PMC9600050/ /pubmed/36290894 http://dx.doi.org/10.3390/curroncol29100617 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Jing
Ning, Yan
Du, Yan
Kang, Yu
Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title_full Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title_fullStr Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title_full_unstemmed Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title_short Lymphadenectomy Benefits Small Cell Carcinoma of Ovary: A Population-Based Analysis
title_sort lymphadenectomy benefits small cell carcinoma of ovary: a population-based analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600050/
https://www.ncbi.nlm.nih.gov/pubmed/36290894
http://dx.doi.org/10.3390/curroncol29100617
work_keys_str_mv AT wangjing lymphadenectomybenefitssmallcellcarcinomaofovaryapopulationbasedanalysis
AT ningyan lymphadenectomybenefitssmallcellcarcinomaofovaryapopulationbasedanalysis
AT duyan lymphadenectomybenefitssmallcellcarcinomaofovaryapopulationbasedanalysis
AT kangyu lymphadenectomybenefitssmallcellcarcinomaofovaryapopulationbasedanalysis